Andreas was a Director in the Autoimmunity, Transplantation & Inflammation group at the Novartis Institutes for BioMedical Research. In this position, he was involved in many aspects of early to late drug development for immune-mediated diseases, taking several modalities to clinical trial and late stage development. He also supported multiple deals with startups. Prior to this, he worked at the Central Research Laboratories at Ciba Geigy, doing research on immune cell trafficking. Andreas studied Biochemistry and Molecular Biology and started his career as a faculty member at the Georgia Institute of Technology.

Christoph joined Anaveon from Roche pRED Immunology, where he led the transition to the late-stage development of Crovalimab, a complement C5 inhibitor. Before that, Christoph was at the Novartis Institutes for BioMedical Research, where he led programs in the stem cell transplant and complement system spaces and conducted trials in cell therapy. He obtained his medical degree and training in stem cell transplantation and internal medicine in Basel, and he completed his postdoc in the immunobiology of graft versus host and graft versus leukemia effects in Bruce Blazar’s group at the University of Minnesota. Christoph continues to practice hematology part-time at the University Hospital Basel.

Laetitia started her carrier in 1999 in academic research at the Max Planck Institute of Immunobiology and Epigenetics in Freiburg, and later at the Institute for Immunology of the LMU in Munich, working on DC and B cells fundamental research with transgenic mice. She joined Micromet (acquired by Amgen) to take part of the development on Bi-Specific T cell engager (BITE) technology and gained experience in toxicology studies. Laetitia spent the last 13 years at Roche, developing in vitro immunosafety assays, investigating the immunogenicity and pharmacodynamic properties of new bi-specific monoclonal antibodies in mice. She holds a bachelor’s degree in Biotechnologies from Lyon Catholic University, France.

Patrizia joined Anaveon after obtaining her PhD degree from ETH Zürich. Her doctoral thesis focused on the generation of novel tumor-specific antibodies and antibody-fusion proteins for the immunotherapy of various cancer types. Before that, Patrizia spent one year at UCSF in the USA as a Junior Scientist, studying the antitumoral effects of oncolytic viruses in combination with immunecheckpoint inhibitors. She holds a Master’s degree in Pharmaceutical Sciences and a Swiss federal diploma as Pharmacist.

Francesca has joined the growing ANAVEON team on the 1st of August 2020. She has 20 years of experience across multiple areas of drug development, reaching from preclinical research, patent management, clinical research to medical affairs. Before joining Anaveon, Francesca held positions at Chiron, Novartis, Menarini and LimmaTech Biologics in immunology and vaccine development. Francesca holds a post-graduate diploma in Clinical Chemistry and Biochemistry from the University of Siena, Italy and her postdoctoral work at Chiron & University of California, San Francisco was on HCV host-pathogen interactions and the role of exosomes.